Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets

Dose Escalation Study Evaluating the Safety of Dimethyl Sulfoxide Cryopreserved Platelets Compared With Liquid Stored Platelets in Patients With Uncontrolled Bleeding

This study is to evaluate the safety of intravenous (IV) infusion of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP) in participants with World Health Organization (WHO) Grade 2 bleed in spite of receiving a transfusion of liquid stored platelets (LSP) in the past 48 hours by collecting adverse events (AEs) and by evaluating coagulation-related parameters to assess the evidence of any thrombotic events after CPP or LSP transfusion.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

After determining eligibility for study participation, 4 sequential cohorts of subjects will receive escalating doses of CPP (Test) or 1 unit of LSP (Control) randomized 6:1 within each cohort. Each sequential cohort will receive the following transfusions starting with the first cohort: 0.5, 1, 2, and 3 units of CPP with an additional single subject in each cohort who will receive 1 unit of LSP for a total of 28 subjects. Assignment to Test and Control platelets for subjects in each cohort will be centrally randomized using an interactive web response system (IWRS). Following the study transfusion, subjects are followed for evidence of transfusion reactions, thrombotic events, other AEs, coagulation-related parameters, and platelet efficacy endpoints. CPP or LSP will be transfused into a patient according to the randomized product and dose assignment within the cohort. Following the transfusion, subjects are followed for the remainder of Study Day 1 and on Study Day 2 for AEs and tested for coagulation markers including fibrinogen, D-dimer, prothrombin fragments 1 + 2 (F 1+2), thrombin antithrombin (TAT), anti-thrombin (AT), prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin generation testing (TGT) results, thromboelastography (TEG) results, and other potential complications of platelet transfusion such as transfusion reactions and thrombotic events including assessment of vital signs (blood pressure, heart rate, respiration rate, and pulse oximetry). A subject is considered to have completed the study for safety evaluation for dose escalation, if he/she receives a study infusion and completed study-related Day 3 procedures.

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Hampshire
      • Lebanon, New Hampshire, United States, 03756
        • Dartmouth-Hitchcock Medical Center
    • Ohio
      • Cincinnati, Ohio, United States, 45267
        • Hoxworth Blood Center
    • Washington
      • Seattle, Washington, United States, 98104
        • Puget Sound Blood Center
      • Seattle, Washington, United States, 98195
        • University of Washington, Division of Hematology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female, at least 18 years of age.
  • Ability to comprehend the study procedures and signed informed consent.
  • If pre-menopausal female, must have a negative serum pregnancy test, and, if of child bearing potential, must be using an acceptable method of contraception.
  • Diagnosed with any the following: acute leukemia (ALL or AML), chronic leukemia (CML, CLL, CMML, or hairy cell leukemia), myelodysplasia, aplasia, hematopoietic or non-hematopoietic solid tumor, or therapy (chemotherapy or radiation) induced bone marrow aplasia or hypoplasia. Either autologous or allogeneic bone marrow transplant or peripheral or cord blood stem cell recipients may be enrolled.
  • WHO grade 2 or greater bleeding.

Exclusion Criteria:

  • Acute or chronic DIC as evidence by D-dimer greater than 8 μg/mL and fibrinogen less than 100 mg (0.1 g)/dL. Both criteria must be met. If data are in the medical record for fibrin degradation products (FDPs), then FDP must be <=40 μg/mL (FDP >40 μg/mL is indicative of DIC).
  • PT or aPTT > 1.3 times the upper limit of normal for the laboratory.
  • History of major operative procedures that required general anesthesia in the past 2 weeks.
  • History of any prior major unprovoked thrombotic events and/or known inherited disorder of coagulation or platelet function (by history) (not to include clots in catheters, etc).
  • A history or diagnosis of immune thrombocytopenia, thrombotic thrombocytopenic purpura, or hemolytic uremic syndrome.
  • Females who are breastfeeding.
  • Veno-occlusive disease or possible veno-occlusive disease.
  • Receiving active, inpatient treatment with anti-platelet drugs and/or full anticoagulation therapy. Note: a heparin flush may be given daily and before and after blood draws to patients with a central line to keep the line patent.
  • Subject previously enrolled in this study and received a study transfusion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort 1 with 0.5 units of CPP
A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
Other Names:
  • dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
Active Comparator: Cohort 1 with 1 unit of LSP
A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
Other Names:
  • liquid stored platelets (LSP)
Experimental: Cohort 2 with 1 unit of CPP
A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
Other Names:
  • dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
Active Comparator: Cohort 2 with 1 unit of LSP
A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
Other Names:
  • liquid stored platelets (LSP)
Experimental: Cohort 3 with 2 units of CPP
A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
Other Names:
  • dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
Active Comparator: Cohort 3 with 1 unit of LSP
A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
Other Names:
  • liquid stored platelets (LSP)
Experimental: Cohort 4 with 3 units of CPP
A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
Other Names:
  • dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
Active Comparator: Cohort 4 with 1 unit of LSP
A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP
Other Names:
  • liquid stored platelets (LSP)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse Events (AEs) by Level of Severity
Time Frame: day of thru 6 days after transfusion
Clinical laboratory [chemistry (serum creatinine, lactate dehydrogenase (LDH), and troponin, and hematology (hemoglobin and hematocrit)] parameters, physical examination findings, electrocardiogram (ECG)] and vital sign AEs summarized by severity.
day of thru 6 days after transfusion
Number of Subject Who Experienced Adverse Events (AEs) for a Specific Severity
Time Frame: day of thru 6 days after transfusion
Number of subjects who experienced AEs at specific levels of severity. Clinical laboratory [chemistry (serum creatinine, lactate dehydrogenase (LDH), and troponin, and hematology (hemoglobin and hematocrit)] parameters, physical examination findings, electrocardiogram (ECG)] and vital signs were evaluated.
day of thru 6 days after transfusion
Number of Subject With Thrombotic Events
Time Frame: 6 days after transfusion
Subjects with any signs or symptoms of thrombotic events.
6 days after transfusion

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Corrected Count Increments (CCI)
Time Frame: Day 1 up to 6 hrs after transfusion and Day 2 approx 24 hrs after transfusion
Corrected Count Increments Expressed in units of mm^2/(µL*10¹¹ platelets) (CCI) in the 6 hour period after the study platelet transfusion and on Day 2 (approximately 24 hours after the study platelet transfusion)
Day 1 up to 6 hrs after transfusion and Day 2 approx 24 hrs after transfusion
Count Increment
Time Frame: On Day 1 up to 6 hours after transfusion and on Day 2 approximately 24 hours after transfusion
Count Increment expressed in units of platelets (x10^3 µL) (CI)
On Day 1 up to 6 hours after transfusion and on Day 2 approximately 24 hours after transfusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sherrill J Slichter, MD, Bloodworks
  • Principal Investigator: Terry B Gernsheimer, MD, University of Washington, Division of Hematology
  • Principal Investigator: Zbigniew Szczepiorkowski, MD, PhD, Center for Transfusion Medicine Research, Lebanon, NH
  • Principal Investigator: Jose A Cancelas-Perez, MD, PhD, Hoxworth Blood Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 5, 2014

Primary Completion (Actual)

July 1, 2016

Study Completion (Actual)

July 17, 2016

Study Registration Dates

First Submitted

February 26, 2014

First Submitted That Met QC Criteria

February 28, 2014

First Posted (Estimate)

March 5, 2014

Study Record Updates

Last Update Posted (Actual)

May 20, 2021

Last Update Submitted That Met QC Criteria

May 19, 2021

Last Verified

May 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thrombocytopenia

Clinical Trials on CPP

3
Subscribe